Neoadjuvant combination immunotherapy for colorectal cancer: clinical and molecular predictors of pathological complete response and safety assessment
Neoadjuvant combination immunotherapy resulted in a favorable pCR rate in patients with CRC. Young age, pretreatment CEA level, TMB level, clinical stage, lymph node metastasis, MSI, MMR, and pole status can be used as indicators of the efficacy of neoadjuvant combination immunotherapy. The incidence of AEs from neoadjuvant combination immunotherapy and surgery was low, indicating that this regimen is safe and feasible.
Authors
- Meng Zhuang (ORCID: https://orcid.org/0000-0002-8868-2952)
- Shiwen Mei
- Yuegang Li (ORCID: https://orcid.org/0000-0001-9115-3448)
- Jianqiang Tang (ORCID: https://orcid.org/0000-0002-9153-6550)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- National Cancer Center (US)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s12876-025-04268-1
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00